“Maxwell Azzarello, the man who died after setting himself on fire while former President Trump's hush money trial was taking place, once worked for the Democrat congressman who flipped Rep. George Santos's seat blue, according to online records.”

From “The Telegraph”


Ozempic maker reveals weight loss pill twice as effective as jab

The maker of weight loss drugs Ozempic and Wegovy has unveiled a new blockbuster obesity pill intended to help patients shed weight dramatically faster than its existing jabs.

Novo Nordisk said early trials for its experimental obesity drug amycretin revealed patients were able to lose more than 13pc of their weight after 12 weeks, compared to weight loss of around 6pc for its Wegovy treatment.

The Danish drugmaker makes both the weight-loss jab Wegovy and Ozempic, a diabetes drug used off-label to treat obesity.

It has been racing to keep up with ballooning demand for the treatments in the past few months, recording a 38pc jump in sales of weight-loss and obesity jabs in 2023 to DKK 215bn (£24bn).

Novo Nordisk chief executive Lars Fruergaard Jorgensen said on Thursday that the obesity market was “a tremendous runway”. Analysts forecast that it could be worth $90bn (£70bn) in the coming years.

Maxim Group Maintains Buy on Lexaria Bioscience, Raises Price Target to $12 LEXX Mar 05, 2024 @ Maxim Group analyst Michael Okunewitch maintains Lexaria Bioscience (NASDAQ: LEXX) with a Buy and raises the price target from $3 to $12.


Copyright © Benzinga. All rights reserved. Write to editorial@benzinga.com with any questions about this content. Benzinga does not provide investment advice.

file:///var/mobile/Library/SMS/Attachments/9c/12/1B67330C-29A9-40A0-A106-7DA31A8A2E53/Screenshot%202024-03-05%20at%209.40.47%E2%80%AFAM.jpeg

Better bring a big check book.

Massive volume and up 20% today.

Should be a lot more chatter over here.

Shockingly unresponsive to the ind application.

Now it’s trading.

Nasdaq

Still delayed…

Still shows delayed.

Are we still delayed? This is taking some time.

1933 Industries Reports Fourth Quarter and 2023 Year-End Financial Results and Posts Record Revenues of $18.3 Million

1933 Industries is pleased to announce its fourth quarter ("Q4 2023") and audited annual financial results for the year ended July 31, 2023 ("Fiscal 2023"). All amounts expressed are in Canadian dollars.

The Company owns 91% of Alternative Medicine Association (AMA), the Company’s cultivation and production subsidiary focused on the medical and adult-use cannabis market, and 100% of consumer-packaged goods manufacturer Infused MFG LLC (Infused). The Company’s revenue is derived from wholesale cannabis sales in Nevada (AMA), and from the sale of hemp-derived wellness products (Infused) under the Canna Hemp™ brand sold across the US via e-commerce at cannahemp.com

Management Commentary
“We are pleased to report record revenues of $18.3 million for fiscal 2023, a 46% increase from fiscal 2022”, said Mr. Paul Rosen, Chairman and CEO of the Company. “We are encouraged by this milestone accomplishment, achieved despite experiencing a considerable disruption in our cultivation facility during the 3rd and 4th quarters while the Company upgraded and retrofitted its facility, which significantly reduced overall revenue during those two quarters. With those upgrades now completed, we remain focused on continuing to increase overall revenue, while also remaining committed to fine tuning our operations and continuing to cut costs. We anticipate that our disciplined approach will allow us to pursue additional growth opportunities in the future.”

Fiscal 2023 and 2022 Consolidated Operating Financing Highlights
Total revenues increased by 46% to $18.3 million in fiscal 2023 from $12.5 million in fiscal 2022. AMA revenues increased by 56% during the reporting period, from $10.9 million in fiscal 2022 to $16.8 million in fiscal 2023.
Expenses were $12.8 million for fiscal 2023 compared to $20.2 million for fiscal 2022, including a non-cash goodwill impairment relating to AMA of $4.6 million.
Gross profit, excluding fair value adjustments, was $0.6 million for fiscal 2023, compared to $3.2 million during the same period in fiscal 2022. Gross profit, after fair value adjustments, was a loss of $0.6 million for fiscal 2023 and a profit of $2.7 million for fiscal 2022. The decrease in gross profit was due to increased production and cultivation costs, delayed harvests, and lower yields while the Company upgraded and retrofitted the building’s complex irrigation and humidification systems during the reporting period.
Net loss and adjusted EBITDA were a loss of $14.0 million and $7.6 million, respectively, for fiscal 2023, largely attributed to the infrastructure updates to the cultivation facility, compared to a loss of $18.1 million and $4.8 million, respectively, for fiscal 2022.
Basic and diluted net loss per share was $0.03 for fiscal 2023, compared to $0.04 for fiscal 2022.
Cash was $1.1 million at the end of the reporting period, compared to $0.3 million in fiscal 2022.

Q4 2023 Compared to Q4 2022 Financing Highlights

Q4 2023 revenues increased to $5.6 million from $2.6 million during the comparable period. The 115% increase in revenue in the current period was primarily due to an increase in AMA revenues resulting from the completion of the retrofit and upgrades to the cultivation facility, and from the plant operating at full capacity. AMA generated significant revenue from the sale of whole cannabis flower.
Gross profit was $0.1 million in the current period compared to a gross loss of $1.9 million in the prior year comparable period.
Expenses were $9.2 million in Q4 2023 compared to $2.2 million in Q4 2022. Included in the increase were higher G&A expenses, a $4.6 million goodwill impairment, higher license fees, taxes, insurance, legal and auditing fees, and increased share-based compensation due to the timing of the vesting of previously issued stock options.

Outstanding Debentures

On November 14, 2023, Holders of 10% Senior Unsecured Convertible Debentures Due December 31, 2023, approved a proposed amendment, which authorizes the Company to pursue at its discretion one of the following settlement options:

The extinguishment of the Debentures upon maturity and the principal debt owed thereunder, excluding any interest in arrears, through the issuance of a new 10% unsecured convertible debenture (the “New Debenture”) with a two year maturity, convertible into units at a price of $0.05 per unit, each unit comprising one common share of the Company and one share purchase warrant, subject to certain acceleration provisions as more particularly defined in the indenture governing the New Debenture, or
The extinguishment of the convertible debentures upon maturity, principal debt and excluding interest in arrears, through the issuance of a Unit to the Debenture holders, each Unit being issued at a deemed price of $0.02 per $1.00 of principal, and one share purchase warrant exercisable into one additional common share of the Company at a price of $0.05 for a period of five years from the date of issuance.

As at the date of these financial statements, the Company has not yet determined which settlement option it will choose.

Financial statements are prepared in accordance with International Financial Reporting Standards. Detailed information regarding the Company’s financial results as well as management's discussion and analysis can be found at https://sedar.com/ and https://1933industries.com/investors/financial-information

Please note the next financial release dates in accordance with the continuous disclosure schedule set out by the British Columbia Securities Commission:

2023 Financial Release Dates
Reporting Quarter Release Date
Q1/2024 January 1, 2024
Q2/2024 April 2, 2024
Q3/2024 July 2, 2024
Q4/YE 2024 November 28, 2024

About 1933 Industries Inc.
1933 Industries is a Nevada-based company, focusing on the cultivation and manufacturing of a large portfolio of cannabis consumer-packaged goods in a variety of formats for both the wholesale and retail markets. Its product offerings through its in-house brands include: wholesale flower, pre-rolls, and extracted products under the AMA and Level X brands for the Nevada market; and Canna Hemp™, a national cannabidiol (CBD) brand of wellness products that includes tinctures, gummies, topicals and sports recovery products. The Company owns 91% of Alternative Medicine Association, LC (AMA) and 100% of Infused MFG LLC (Infused). For more information, please visit www.1933industries.com

For further information please contact:
Alexia Helgason, VP, IR, Marketing, Media
604-728-4407
alexia@1933industries.com

Yep, we just need a catalyst.

If a select group is acquiring 15%…they must be very close to achieving their number. Not sure what happens to the price when they are done…without any of the expected press releases that we r waiting on?

After hours…big jump.

Something is afoot.

Still moving…insider leak or speculation?

Maybe a hypothesis…

All very interesting though.

No…Ted is not one to speculate…

Sorry, a bit late.

Facebook

Phil Rowat:
“With the recent signing of the SulfoSyn deal, I thought I'd bring this Nov. 2022 news release to the front of mind. In January we signed the former President of GW Pharma as a Strategic Advisor to Lexaria and Gillian Dines, Chief Science Officer of Juvenescence once worked for both GW Pharma and Jazz Pharmaceuticals which now owns Epidiolex. Will we see a deal between Jazz and Lexaria to license DehydraTECH?”

🏃‍♂️🏃‍♂️🏃‍♂️🏃‍♂️🏃‍♂️🏃‍♂️🏃‍♂️

Looks like we might have a runner…

A swing and a miss…

But only after they have major news and they stay where they are…

I would doubt it…maybe 10 or 20 to 1…

South Carolina Republican introduces bill to decriminalize marijuana at federal level

Rep. Nancy Mace, a first-term Republican from South Carolina, introduced a bill Monday to decriminalize cannabis at the federal level, which she hopes will garner more GOP support for the legalization movement.

"This legislation, I believe, has something good for everyone, whether you're a Democrat or a Republican," Mace told reporters outside the Capitol, where she introduced her States Reform Act.

Even though it is legal in 18 states, with medical use permissible in 37 states, marijuana is illegal under federal law.

Mace's bill would strip cannabis of its classification as a Schedule I drug under the Controlled Substances Act, which makes possession of marijuana a crime. Her office said the legislation aims to end criminalization "in a manner consistent with the rights of states to determine what level of cannabis reform or legalization each state wants to regulate, or not."

The measure also would allow for expungement of federal convictions in nonviolent cases and provide a framework for federal regulation and enforcement in states that allow the sale of marijuana.

Sales would be prohibited to people under 21, Mace said, adding that the bill would establish cannabis regulations similar to restrictions on alcohol.

The legislation further calls for a 3 percent federal excise tax on marijuana, lower than the level in a Democratic bill that is making its way through the House.

"I kept it very low," Mace said, pointing to high taxes on marijuana in California, which she said have stoked black market sales. "It's got to be under 4 percent to reduce the opportunity for illicit markets."


A Gallup poll released this month found that 68 percent of Americans support legalizing marijuana, with backing from 83 percent of Democrats and 50 percent of Republicans.

Mace said her bill already has five Republican co-sponsors.

"My main goal is to get as much Republican support as I can initially, and we're hearing great feedback," she said.

But the chair of the South Carolina GOP, Drew McKissick, denounced Mace's effort.

"Unequivocally, the South Carolina Republican Party is against any effort to legalize, decriminalize the use of controlled substances, and that includes this bill. Since this will have widespread negative impacts, from rising crime, violence, and mental health issues in children, I think it's a safe bet to say most Republicans will be against it too," McKissick said in a statement.

The Democratic-controlled House passed a broader but similar bill late last year called the Marijuana Opportunity Reinvestment and Expungement Act. A total of 222 Democrats and five Republicans voted for the legislation, while six Democrats and 158 Republicans voted against it.

The bill died in the Senate, which at the time was controlled by Republicans. House Democrats are trying to pass the legislation.

Senate Majority Leader Chuck Schumer, D-N.Y., circulated a draft bill this year that would decriminalize marijuana, called the Cannabis Administration and Opportunity Act, but he acknowledged he doesn't have the votes to get it passed. The legislation would need 60 votes to pass in the Senate, and a number of Republican and moderate Democratic senators have argued against quick action, urging further studies on the drug before it is decriminalized

South Carolina Republican introduces bill to decriminalize marijuana at federal level

Rep. Nancy Mace, a first-term Republican from South Carolina, introduced a bill Monday to decriminalize cannabis at the federal level, which she hopes will garner more GOP support for the legalization movement.

"This legislation, I believe, has something good for everyone, whether you're a Democrat or a Republican," Mace told reporters outside the Capitol, where she introduced her States Reform Act.

Even though it is legal in 18 states, with medical use permissible in 37 states, marijuana is illegal under federal law.

Mace's bill would strip cannabis of its classification as a Schedule I drug under the Controlled Substances Act, which makes possession of marijuana a crime. Her office said the legislation aims to end criminalization "in a manner consistent with the rights of states to determine what level of cannabis reform or legalization each state wants to regulate, or not."

The measure also would allow for expungement of federal convictions in nonviolent cases and provide a framework for federal regulation and enforcement in states that allow the sale of marijuana.

Sales would be prohibited to people under 21, Mace said, adding that the bill would establish cannabis regulations similar to restrictions on alcohol.

The legislation further calls for a 3 percent federal excise tax on marijuana, lower than the level in a Democratic bill that is making its way through the House.

"I kept it very low," Mace said, pointing to high taxes on marijuana in California, which she said have stoked black market sales. "It's got to be under 4 percent to reduce the opportunity for illicit markets."


A Gallup poll released this month found that 68 percent of Americans support legalizing marijuana, with backing from 83 percent of Democrats and 50 percent of Republicans.

Mace said her bill already has five Republican co-sponsors.

"My main goal is to get as much Republican support as I can initially, and we're hearing great feedback," she said.

But the chair of the South Carolina GOP, Drew McKissick, denounced Mace's effort.

"Unequivocally, the South Carolina Republican Party is against any effort to legalize, decriminalize the use of controlled substances, and that includes this bill. Since this will have widespread negative impacts, from rising crime, violence, and mental health issues in children, I think it's a safe bet to say most Republicans will be against it too," McKissick said in a statement.

The Democratic-controlled House passed a broader but similar bill late last year called the Marijuana Opportunity Reinvestment and Expungement Act. A total of 222 Democrats and five Republicans voted for the legislation, while six Democrats and 158 Republicans voted against it.

The bill died in the Senate, which at the time was controlled by Republicans. House Democrats are trying to pass the legislation.

Senate Majority Leader Chuck Schumer, D-N.Y., circulated a draft bill this year that would decriminalize marijuana, called the Cannabis Administration and Opportunity Act, but he acknowledged he doesn't have the votes to get it passed. The legislation would need 60 votes to pass in the Senate, and a number of Republican and moderate Democratic senators have argued against quick action, urging further studies on the drug before it is decriminalized

South Carolina Republican introduces bill to decriminalize marijuana at federal level

Rep. Nancy Mace, a first-term Republican from South Carolina, introduced a bill Monday to decriminalize cannabis at the federal level, which she hopes will garner more GOP support for the legalization movement.

"This legislation, I believe, has something good for everyone, whether you're a Democrat or a Republican," Mace told reporters outside the Capitol, where she introduced her States Reform Act.

Even though it is legal in 18 states, with medical use permissible in 37 states, marijuana is illegal under federal law.

Mace's bill would strip cannabis of its classification as a Schedule I drug under the Controlled Substances Act, which makes possession of marijuana a crime. Her office said the legislation aims to end criminalization "in a manner consistent with the rights of states to determine what level of cannabis reform or legalization each state wants to regulate, or not."

The measure also would allow for expungement of federal convictions in nonviolent cases and provide a framework for federal regulation and enforcement in states that allow the sale of marijuana.

Sales would be prohibited to people under 21, Mace said, adding that the bill would establish cannabis regulations similar to restrictions on alcohol.

The legislation further calls for a 3 percent federal excise tax on marijuana, lower than the level in a Democratic bill that is making its way through the House.

"I kept it very low," Mace said, pointing to high taxes on marijuana in California, which she said have stoked black market sales. "It's got to be under 4 percent to reduce the opportunity for illicit markets."


A Gallup poll released this month found that 68 percent of Americans support legalizing marijuana, with backing from 83 percent of Democrats and 50 percent of Republicans.

Mace said her bill already has five Republican co-sponsors.

"My main goal is to get as much Republican support as I can initially, and we're hearing great feedback," she said.

But the chair of the South Carolina GOP, Drew McKissick, denounced Mace's effort.

"Unequivocally, the South Carolina Republican Party is against any effort to legalize, decriminalize the use of controlled substances, and that includes this bill. Since this will have widespread negative impacts, from rising crime, violence, and mental health issues in children, I think it's a safe bet to say most Republicans will be against it too," McKissick said in a statement.

The Democratic-controlled House passed a broader but similar bill late last year called the Marijuana Opportunity Reinvestment and Expungement Act. A total of 222 Democrats and five Republicans voted for the legislation, while six Democrats and 158 Republicans voted against it.

The bill died in the Senate, which at the time was controlled by Republicans. House Democrats are trying to pass the legislation.

Senate Majority Leader Chuck Schumer, D-N.Y., circulated a draft bill this year that would decriminalize marijuana, called the Cannabis Administration and Opportunity Act, but he acknowledged he doesn't have the votes to get it passed. The legislation would need 60 votes to pass in the Senate, and a number of Republican and moderate Democratic senators have argued against quick action, urging further studies on the drug before it is decriminalized.

This can only be construed as a negative…certainly hope, somehow, that I am wrong.

Brian W Quigley
INDEPENDENT DIRECTOR

Brian W. Quigley founded Green Sky Strategy LLC. Currently, he is Chief Operating Officer for Respira Technologies, Inc. Mr. Quigley is also on the board of Lexaria Bioscience Corp., Virginia Foundation for Independent Colleges, Science Museum of Virginia Foundation, Inc. and MustGrow Biologics Corp.

Mr. Quigley previously held the position of President & Chief Executive Officer of Altria Group, Inc. President & Chief Executive Officer at U.S. Smokeless Tobacco Co. LLC, President & Chief Executive Officer for US Smokeless Tobacco Manufacturing Co. LLC and President & Chief Executive Officer for Nu Mark Innovations, Ltd. (which are all subsidiaries of Altria Group, Inc.) and Partner at Green Sky Strategy LLC.

He received an undergraduate degree from the University of New Hampshire.

State approves $100M to boost marijuana retailers
TRD Staff

Photo Illustration of California Governor Gavin Newsom (Getty)
California approved a plan to provide $100 million to boost its legal marijuana industry. While sales have remained steady, many retailers have been suffering, stifled by a mix of local regulations and fees, and competition from unlicensed pot shops.

The state legislature approved the grant funding Monday for cities and counties, hoping to help existing cannabis businesses convert temporary licenses into permanent ones, according to the Los Angeles Times. Licenses have to be renewed each year.

Los Angeles will receive $22 million of the funding, according to the report. Long Beach, San Francisco, and Oakland are among 17 other cities that are set to receive funds.

The state set a path to formal licensing when voters approved Proposition 64 in 2016, which regulates and taxes marijuana use. Officials expected to grant licenses to 6,000 pot shops in the first few years, but only about 1,000 have been issued for retail and delivery firms.

Los Angeles has tried to crack down on the many illegal retail dispensaries that have flowered in recent years. In 2019, the city had more illegal shops than licensed ones, because of the cost burden of following city regulations and obtaining licenses.

With the new grant funding, cities and counties can hire experts to help businesses move through the licensing process, the report noted.

Unlicensed cannabis shops also pose issues for brokers and landlords. In L.A., the city sued two brokers at Daum commercial brokerage in 2019, saying the pair arranged a lease to an unlicensed pot shop in Central Alameda. The judge eventually dismissed the suit.

Gov. Gavin Newsom is also considering whether to give cannabis businesses an additional six months to transition to permanent licenses. Businesses currently have until Jan. 1, 2022, to comply with state environmental laws.

Many marijuana businesses could shut down if they don’t obtain a permanent license before the deadline and aren’t supported through the process with the new state grants. Closed businesses would hit the retail sector hard, as marijuana sales have remained steady throughout the country during the pandemic.

[LAT] — Isabella Farr

Not a lot of volume.

Let’s hope it is not another Betamax.

Finally up and running...and I do mean running...

CSE: IMCC) (OTCMKTS: IMCNF) has concluded its listing process and is expected to start trading on the NASDAQ on March 1, 2021.

Rocket ship that is going straight up...

My oh My...up 140%+ now for the day.

Now it has doubled today...up 100%.